

# Accepted Manuscript

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa, William Sun, Michael Montgomery, Srdan Verstovsek

PII: S2152-2650(17)30163-5

DOI: [10.1016/j.clml.2017.05.015](https://doi.org/10.1016/j.clml.2017.05.015)

Reference: CLML 931


To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 10 March 2017

Accepted Date: 5 May 2017

Please cite this article as: Miller CB, Komrokji RS, Mesa RA, Sun W, Montgomery M, Verstovsek S, Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I, *Clinical Lymphoma, Myeloma and Leukemia* (2017), doi: 10.1016/j.clml.2017.05.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



COMFORT-I Practical Measures  
Final Draft; March 9, 2017

## Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Carole B. Miller,<sup>a</sup> Rami S. Komrokji,<sup>b</sup> Ruben A. Mesa,<sup>c</sup> William Sun,<sup>d</sup> Michael Montgomery,<sup>d</sup> Srdan Verstovsek<sup>e</sup>

<sup>a</sup>Saint Agnes Cancer Institute, Baltimore, MD, USA; <sup>b</sup>Moffitt Cancer Center, Tampa, FL, USA; <sup>c</sup>Division of Hematology and Medical Oncology, Mayo Clinic Cancer Center, Scottsdale, AZ, USA; <sup>d</sup>Incyte Corporation, Wilmington, DE, USA; <sup>e</sup>Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Address correspondence to:

Carole B. Miller  
Saint Agnes Cancer Institute  
900 S Caton Ave  
Baltimore, MD 21229  
Tel: 667-234-2909  
Fax: 667-234-3517  
Email: [cmiller@stagnes.org](mailto:cmiller@stagnes.org)

Author information:

Rami S. Komrokji  
Moffitt Cancer Center  
12902 USF Magnolia Dr  
Tampa, FL 33612  
Email: [rami.komrokji@moffitt.org](mailto:rami.komrokji@moffitt.org)

Ruben A. Mesa  
Division of Hematology and Medical  
Oncology  
Mayo Clinic Cancer Center  
13400 E Shea Blvd  
Scottsdale, AZ 85258  
Email: [mesa.ruben@mayo.edu](mailto:mesa.ruben@mayo.edu)

William Sun  
Incyte Corporation  
1801 Augustine Cut Off  
Wilmington, DE 19803  
Email: [wsun@incyte.com](mailto:wsun@incyte.com)

Michael Montgomery  
Incyte Corporation  
1801 Augustine Cut Off  
Wilmington, DE 19803  
Email: [mmontgomery@incyte.com](mailto:mmontgomery@incyte.com)

Srdan Verstovsek  
Department of Leukemia, Division of  
Cancer Medicine  
The University of Texas MD Anderson  
Cancer Center  
1515 Holcombe Blvd  
Houston, TX 77030  
Email: [sverstov@mdanderson.org](mailto:sverstov@mdanderson.org)

Running head:

COMFORT-I Practical Measures

Journal:

*Clinical Lymphoma, Myeloma & Leukemia*

Word count:

2139 (limit, 2000-8000)

Tables/Figures:

1/6 (limit, 7 total)

Download English Version:

<https://daneshyari.com/en/article/5582016>

Download Persian Version:

<https://daneshyari.com/article/5582016>

[Daneshyari.com](https://daneshyari.com)